Scarica l'app Stockscreener
71.19
1.59%
-1.15
Precedente Chiudi:
$72.34
Aprire:
$73.21
Volume 24 ore:
1.97M
Relative Volume:
0.91
Capitalizzazione di mercato:
$11.76B
Reddito:
$943.38M
Utile/perdita netta:
$-380.99M
Rapporto P/E:
-28.86
EPS:
-2.4667
Flusso di cassa netto:
$-325.67M
1 W Prestazione:
-3.85%
1M Prestazione:
-11.67%
6M Prestazione:
+12.71%
1 anno Prestazione:
+116.38%
Intervallo 1D:
$70.42
$74.16
Intervallo di 1 settimana:
$70.42
$77.03
Portata 52W:
$23.95
$86.74
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Nome
Ionis Pharmaceuticals Inc
Settore
Industria
Telefono
(760) 931-9200
Indirizzo
2855 GAZELLE COURT, CARLSBAD, CA
Compare IONS vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
71.19 | 11.76B | 943.38M | -380.99M | -325.67M | -2.4667 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2025-10-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-09-26 | Aggiornamento | Goldman | Sell → Neutral |
| 2025-09-03 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-31 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-01 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-04-07 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-31 | Iniziato | Redburn Atlantic | Neutral |
| 2024-08-02 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | Ripresa | Jefferies | Buy |
| 2024-06-14 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-10-23 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-09-29 | Iniziato | Raymond James | Strong Buy |
| 2023-07-31 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-06-07 | Ripresa | Piper Sandler | Overweight |
| 2023-05-04 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-03-21 | Iniziato | Bernstein | Underperform |
| 2022-12-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | Ripresa | Morgan Stanley | Overweight |
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
| 2022-03-31 | Ripresa | Piper Sandler | Overweight |
| 2022-03-01 | Iniziato | Citigroup | Sell |
| 2022-03-01 | Iniziato | Guggenheim | Buy |
| 2022-02-01 | Downgrade | BofA Securities | Buy → Underperform |
| 2021-12-14 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | Aggiornamento | UBS | Sell → Neutral |
| 2021-03-01 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2020-12-16 | Iniziato | UBS | Sell |
| 2020-12-15 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2020-09-14 | Ripresa | JP Morgan | Neutral |
| 2020-09-02 | Iniziato | The Benchmark Company | Hold |
| 2020-06-01 | Ripresa | Oppenheimer | Outperform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-12-13 | Iniziato | Oppenheimer | Outperform |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-11-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | Reiterato | Stifel | Hold |
| 2018-08-07 | Reiterato | Stifel | Hold |
| 2018-05-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2017-10-06 | Ripresa | Goldman | Sell |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-08-09 | Reiterato | Stifel | Hold |
| 2017-03-10 | Downgrade | Goldman | Neutral → Sell |
| 2016-12-28 | Reiterato | BMO Capital Markets | Outperform |
| 2016-12-27 | Reiterato | Leerink Partners | Mkt Perform |
Mostra tutto
Ionis Pharmaceuticals Inc Borsa (IONS) Ultime notizie
Ionis outlines >$2B peak sales target for olezarsen as new launches and pipeline catalysts drive 2026 outlook - MSN
IONS SEC FilingsIonis Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
Connor Clark & Lunn Investment Management Ltd. Raises Stake in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Atika Capital Management LLC Invests $1.41 Million in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Insider Sell: Brett Monia Sells 160,773 Shares of Ionis Pharmaceuticals Inc (IONS) - GuruFocus
Ionis Pharmaceuticals (NASDAQ:IONS) CEO Sells $9,525,584.00 in Stock - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) CEO Brett Monia Sells 34,103 Shares of Stock - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells $2,827,460.45 in Stock - MarketBeat
Ionis Pharmaceuticals Presents at Barclays Healthcare Conference - National Today
Ionis Pharmaceuticals (IONS) EVP executes 10b5-1 sale of 10,148 shares - Stock Titan
Ionis (NASDAQ: IONS) EVP sells 37,277 shares under 10b5-1 plan - Stock Titan
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy - Biogen
Capital World Investors Has $832.32 Million Holdings in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis Pharma director Diaz sells $4.35m in IONS stock By Investing.com - Investing.com Nigeria
IONS (Nasdaq: IONS) insider notice: 37,277 shares from option exercises - Stock Titan
Ionis pharma director Loscalzo sells $82k in shares - Investing.com Nigeria
Ionis pharma director Klein sells $1.7 million in IONS stock - Investing.com Nigeria
Ionis Pharmaceuticals at Leerink Global Healthcare: Strategic Moves in 2026 By Investing.com - Investing.com Canada
Ionis Pharmaceuticals Announces Board Changes: Parshall and Wender to Retire, Reikes Rejoins in 2026 - Minichart
Ionis announces changes to Board of Directors - pharmiweb.com
Ionis Pharmaceuticals Announces Board Retirements and New Appointment - TipRanks
Ionis Pharmaceuticals (NASDAQ: IONS) plans board refresh as Parshall, Wender retire and Reikes returns - Stock Titan
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Ionis Pharmaceuticals, Inc. $IONS Position Raised by Rhenman & Partners Asset Management AB - MarketBeat
GW&K Investment Management LLC Sells 184,823 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
DCF Advisers LLC Has $7.09 Million Stock Holdings in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
August 21st Options Now Available For Ionis Pharmaceuticals (IONS) - Nasdaq
Ionis pharma director Loscalzo sells $82k in shares By Investing.com - Investing.com UK
Insider Sell: Joseph Loscalzo Sells Shares of Ionis Pharmaceuticals Inc (IONS) - GuruFocus
Insider Selling: Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells 20,106 Shares of Stock - MarketBeat
C Frank Bennett Sells 85,089 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock - MarketBeat
Allene Diaz Sells 54,878 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock - MarketBeat
Ionis Pharma director Diaz sells $4.35m in IONS stock - Investing.com South Africa
Ionis Pharma EVP Devers sells $1.59 million in IONS stock By Investing.com - Investing.com Canada
Ionis pharma director Klein sells $1.7 million in IONS stock By Investing.com - Investing.com Australia
ARK Investment Management LLC Decreases Holdings in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Amova Asset Management Americas Inc. Decreases Holdings in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis EVP exercises options and sells shares | IONS SEC FilingForm 4 - Stock Titan
Legato Capital Management LLC Takes Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
HC Wainwright Analysts Raise Earnings Estimates for IONS - MarketBeat
American Century Companies Inc. Grows Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis Pharmaceuticals (IONS) Receives Price Target Raise to $104 by Leerink Partners | IONS Stock News - GuruFocus
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $104.00 at Leerink Partners - MarketBeat
Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: A Biotech Powerhouse with 15.60% Upside Potential - DirectorsTalk Interviews
Rafferty Asset Management LLC Decreases Stake in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Oligonucleotides Global Markets, 2022-2024 & 2025-2030, Profiles of Major PlayersAlnylam Pharmaceuticals, Biogen/Ionis Pharmaceuticals, Novartis, and Sarepta Therapeutics - Yahoo Finance
Ionis Pharmaceuticals, Inc. $IONS Shares Bought by Envestnet Asset Management Inc. - MarketBeat
Ionis Priority Review And DAWNZERA Data Reframe Rare Disease Growth Story - Yahoo Finance
Ionis FDA And Phase 3 Updates Reframe Rare Disease Valuation Story - simplywall.st
Ionis Pharmaceuticals CEO Teases Late-June Olezarsen Launch After FDA Priority Review Acceptance - Yahoo Finance
Olezarsen Priority Review and Expanding Rare Disease Franchise Could Be A Game Changer For Ionis (IONS) - Yahoo Finance
Ionis Pharmaceuticals Inc Azioni (IONS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):